Vertex and CRISPR Therapeutics announce research partnership

US-based Vertex Pharmaceuticals and CRISPR Therapeutics have agreed a research collaboration to discover and develop new treatments for genetic causes of human diseases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Vertex signs $100m CRISPR deal to use sickle cell treatment

14 December 2023 Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

Americas

CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology

13 November 2018 Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

Americas

FDA lifts hold on first human CRISPR trial

17 October 2018 The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.

More on this story

Biotechnology

Vertex signs $100m CRISPR deal to use sickle cell treatment

14 December 2023 Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

Americas

CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology

13 November 2018 Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

Americas

FDA lifts hold on first human CRISPR trial

17 October 2018 The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.

More on this story

Biotechnology

Vertex signs $100m CRISPR deal to use sickle cell treatment

14 December 2023 Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

Americas

CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology

13 November 2018 Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

Americas

FDA lifts hold on first human CRISPR trial

17 October 2018 The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.